Moderna 2022 Priorities and Capital Allocation

Summary . SARS-COV-2 continues to evolve rapidly with multiple new variants and recombinants. circulating globally Real world data demonstrate the effectiveness of a booster shot (third dose) of mRNA- 1273 against evolving variants of concern. A fourth dose of mRNA-1273 shows good marginal effectiveness when compared to a third dose against infection, symptomatic infection and severe disease in a high-risk population We believe people at high-risk would benefit from annual boosting Slide 13 moderna

View entire presentation